The Differential Characteristics Between Severe Fever With Thrombocytopenia Syndrome and Hemorrhagic Fever With Renal Syndrome in the Endemic Regions

Qing-Bin Lu,1,a Fa-Chun Jiang,3,a Ling-Ling Mao,4 Xue-Sheng Liu,4
Ning Wang,4 YTong-Yun Zhou,5 Ke Dai,6 Zhen-Dong Yang,7 Li-Yan Dong,3 Ning Cui,7 Xiao-Ai Zhang,2 Shao-Fei Zhang,2 Pan-He Zhang,2 Li-Qun Fang,2 and Wei Liu2

1Department of Laboratorial Science and Technology, School of Public Health, Peking University, Beijing, People’s Republic of China; 2State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, People’s Republic of China; 3Division of Infectious Disease, Qingdao Center for Disease Control and Prevention, Qingdao, People’s Republic of China; 4Liaoning Center for Disease Control and Prevention, Shenyang, People’s Republic of China; 5Department of Microbiology, Graduate School of Mupanjiang Normal University, Mupanjiang, People’s Republic of China; 6China National Accreditation Service for Conformity Assessment, Beijing, People’s Republic of China; 7The 990 Hospital of Chinese People’s Liberation Army Joint Logistic Support Force, Xinyang, People’s Republic of China

Received 10 August 2019; editorial decision 30 October 2019; accepted 1 November 2019.
Correspondence: Wei Liu, MD, State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, 20 DongDa Street, Fengtai District, Beijing 100071, P. R. China (liuwei@bmi.ac.cn or lwbime@163.com).

Open Forum Infectious Diseases®
© The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
DOI: 10.1093/ofid/ofz477

An effective differentiation between severe fever with thrombocytopenia syndrome and hemorrhagic fever with renal syndrome was attained by a model considering patients’ age, mouse/tick contact, presence of blush, low back pain, diarrhea, enlarged lymph nodes, and white blood cell count.

Keywords. differential diagnosis; hemorrhagic fever with renal syndrome; severe fever with thrombocytopenia syndrome.

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral hemorrhagic fever (VHF) caused by SFTS virus (SFTSV). The disease was first discovered in China in 2010 and is mainly transmitted by tick bite and occasionally from person-to-person spread via SFTSV-infected blood or fluid [1, 2]. By the end of 2018, more than 8000 clinically diagnosed SFTS patients were reported in China [3], and over 1000 cases were reported from Japan [4], South Korea [5], and Vietnam [6], with a case fatality rate ranging from 5% [3] to 30% [2]. Another important VHF that is life threatening among large populations is hemorrhagic fever with renal syndrome (HFRS), which is caused by hantavirus and is often carried and transmitted by rodents [7]. Although HFRS cases occur worldwide, approximately 90% of the cases were reported in China, Japan, and South Korea [8, 9], which shows a highly similar geographic distribution to that of SFTS. Epidemiologically, both SFTS and HFRS are prevalent in rural areas, and farmers and outsiders are susceptible to infection through high-risk exposure to vector or host. Clinically, the 2 VHFs shared common features, with atypical and indistinguishable febrile disease observed at acute infection, subsequently followed by a critical or recovery phase. For those with adverse disease outcomes, both infections might rapidly progress into severe illness, which is characterized by hemorrhagic fever or multiple organ dysregulation. All of these features made differential diagnosis difficult in the endemic regions where both diseases are prevalent. A recent study reported the discovery of 4 patients with SFTSV infection out of 55 hantavirus-negative patients in Shandong Province, a long existing endemic region for HFRS [10]. We hypothesize that, similar to SFTS, HFRS can be misdiagnosed. In this report, we conducted a retrospective study in SFTS-endemic and HFRS-endemic regions, respectively, to identify the misdiagnosis of 2 VHF diseases and to attain differential diagnosis based on complete and detailed clinical data recording.

METHODS

The study was performed in 3 regions, where both SFTS and HFRS have been reported (Supplemental Figure 1). The sera sample and epidemiological database of clinically diagnosed HFRS patients had been collected from the Liaoning Center for Disease Control and Prevention (CDC) and Qingdao CDC. The clinically diagnosed patients and laboratory-confirmed patients had been defined by the criteria for SFTS [11] and HFRS [12], respectively, that was released by National Health Commission of the People’s Republic of China (also see the Supplemental Material and Methods). The sera sample and epidemiological database of clinically diagnosed SFTS patients had been collected from Liaoning CDC and the People’s Liberation Army 990 hospital in Xinyang city, Henan province. All sera samples were collected immediately after hospital admission and tested for hantavirus and SFTSV infection at the acute phase of illness.

Data regarding demographic, epidemiological, and pretreatment clinical information were recorded by using a standard questionnaire released by China CDC.

In the current study, by using the available sera sample, we retested clinically diagnosed HFRS patients for SFTSV ribonucleic acid by applying real-time reverse-transcription polymerase chain reaction (RT-PCR) [2] and anti-SFTSV immunoglobulin (Ig)M antibody by applying immunofluorescence assay (IFA),...
and we retested clinically diagnosed SFTS patients for hantavirus by applying real-time RT-PCR and anti-hantavirus IgM antibody by using a commercial ELISA Kit (Wantai Biological Pharmacy, Beijing, China) (Supplemental Material and Methods). The available epidemiological and clinical datasets were retrospectively used for the current analysis. The study protocol was approved by the Review Board of Beijing Institute of Microbiology and Epidemiology. The SFTS and HFRS differentiation was performed using logistic regression model, and the differential factors were identified by using the classification tree with a Chi-square Automatic Interaction Detection (CHAID) model. Receiver operating characteristic (ROC) curves were constructed for evaluation of the scoring model. A 2-sided $P < .05$ was considered statistically significant. All analyses were performed using STATA 14.0 (Stata Corp LLP, College Station, TX) and SPSS version 22 (IBM Corp., Armonk, NY).

RESULTS

A total of 1546 patients were enrolled. In the SFTS-endemic region, 943 clinically diagnosed SFTS patients were screened, and 588 (62.4%) were positive for SFTSV infection, including 5 (0.9%) with hantavirus infection (coinfection group). Among the remaining 355 (38.6%) SFTSV-negative patients, 21 (5.9%) were positive for hantavirus infection (defined as the misdiagnosed group) (Supplemental Table 1). In comparison with SFTSV-positive patients, the misdiagnosed patients had significantly younger age, shorter interval from disease onset to hospital admission, higher frequency of mouse contact, and lower frequency of tick bite (all $P < .05$). Abdominal pain, nausea, and enlarged lymph nodes were less frequently seen among the misdiagnosed patients compared with the SFTSV-positive patients (all $P < .05$). For 2 hallmark laboratory features of SFTS, leukopenia was underrepresented in the misdiagnosed patients ($P < .001$), whereas thrombocytopenia was seen with comparable frequency (Supplemental Table 1).

In the HFRS-endemic regions, 603 clinically diagnosed HFRS patients were screened, and 348 (57.7%) were positive for hantavirus infection, including 4 (1.1%) with SFTSV infection (coinfection group). Among the remaining 255 (42.3%) hantavirus-negative patients, 8 (3.1%) were positive for SFTSV infection (misdiagnosed group). The misdiagnosed SFTS patients had older age, higher frequency of tick bite, higher body temperature, and higher presence of enlarged lymph nodes, thrombocytopenia, and leukopenia (all $P < .05$) (Supplemental Table 2).

The hantavirus-SFTSV coinfection rate (0.6%, 9 of 1546) was lower than the expected rate that was calculated from SFTSV single infection rate multiplied by the hantavirus single infection rate, ie, 36.2% multiplied by 24.2%, indicating a lower tendency of coinfection between the 2 pathogens. The coinfection group did not reveal significantly higher proportions of clinical features than the SFTS alone or HFRS alone group (Supplemental Table 3), indicating no more serious outcome originated from coinfection, which might be biased by the small sample size.

To attain clinical differentiation between 2 diseases, the laboratory-confirmed SFTS ($n = 591$) and HFRS patients ($n = 365$) were grouped for the evaluation of 33 variables regarding demographic, epidemiological, and clinical characteristics (Table 1). Most of the variables displayed significant differences between 2 groups, and 18 significant variables showed area under the curve (AUC) $>0.600$ and were further entered into the multiple logistic regression model to attain better discrimination power. On the ROC curve obtained from the model, the AUC was 0.985 (95% confidence interval [CI], 0.979–0.992), with 92.6% (95% CI, 89.4%–95.1%) sensitivity and 95.4% (95% CI, 93.4%–97.0%) specificity (Supplemental Figure 2). Patients of younger age that had mouse contact history, clinical presence of blush, low back pain, and higher level of white blood cell (WBC) counts ($≥4.74 \times 10^9$/L) were significantly associated with hantavirus infection rather than SFTSV infection. Patients of older age that had tick bite history, presented with diarrhea, had enlarged lymph nodes, and had lower level of WBC counts ($<4.74 \times 10^9$/L) were significantly associated with SFTSV infection rather than hantavirus infection (Supplemental Table 4). The classification tree was generated based on the significant variables in the multiple logistic analysis. Patients with WBC $≤2.7 \times 10^9$/L without mouse contact history or low back pain (Node 19), or patients with WBC of $2.7 \times 10^9$/L–$3.4 \times 10^9$/L and enlarged lymph nodes (Node 10) were classified as SFTS patients. Patients with WBC of $7.6 \times 10^9$/L–$8.4 \times 10^9$/L (Node 14) and low back pain or patients with both WBC $>8.4 \times 10^9$/L and mouse contact history (Nodes 16 and Node 18) were classified as HFRS patients (Supplemental Figure 3).

DISCUSSION

In rural regions where both HFRS and SFTS circulate, a common dilemma in diagnosis is the lack of molecular or immunological assay in clinical medical care. The current gold standard for diagnosis is IFA or enzyme-linked immunosorbent assay test or molecular test by PCR [10], whereas their widespread use is limited due to lack of instrument or technical expertise in rural areas where disease circulated. Although the case definition of SFTS or HFRS defined by classic clinical features is sufficiently sensitive to capture most of the likely cases, there are other patients with atypical manifestation that was missed by the clinical definition. In this study, we provided evidence showing that a certain proportion of hantavirus infection was found in patients who were initially diagnosed with SFTS, and vice versa a certain proportion of SFTSV infection existed in patients treated for HFRS. The presence of low back pain, orbital pain, neck red and chest red, and headache, which are considered to be typical...
Table 1. The Basic and Clinical Differentiation Between the Laboratory-Confirmed SFTS and HFRS Patients

| Characteristics                        | SFTS (n = 591) | HFRS (n = 365) | P value | AUC  |
|----------------------------------------|----------------|----------------|---------|------|
| Age, year, mean ± SD                   | 62 ± 12        | 46 ± 14        | <.001a  | 0.812|
| <45                                    | 55 (9.3)       | 161 (44.1)     | <.001b  | 0.784|
| 45-60                                  | 167 (28.3)     | 152 (41.6)     |         |      |
| ≥60                                    | 369 (62.4)     | 52 (14.3)      |         |      |
| Sex, male                              | 279 (46.7)     | 269 (73.7)     | <.001b  | 0.633|
| Days from onset to admission, median (IQR) | 5 (3-6)     | 4 (2-6)        | <.001c  | 0.433|
| Recent contact with Mouse              | 31 (5.3)       | 164 (44.9)     | <.001b  | 0.698|
| Mosquito (n = 461)                     | 20 (9.0)       | 6 (2.5)        | .003b   | 0.533|
| Tick                                   | 151 (25.6)     | 2 (0.6)        | <.001d  | 0.625|
| Mice faeces                            | 10 (4.6)       | 2 (0.8)        | .016d   | 0.519|
| Clinical Manifestation, n (%)          |                |                |         |      |
| Headache                               | 187 (31.6)     | 253 (69.3)     | <.001b  | 0.668|
| Highest temperature, °C, mean ± SD     | 38.9 ± 0.6     | 39.0 ± 0.6     | .100c   | 0.543|
| Low back pain (n = 634)                | 81 (28.9)      | 210 (59.3)     | <.001b  | 0.652|
| Orbital pain (n = 634)                 | 17 (6.1)       | 100 (28.3)     | <.001b  | 0.611|
| Arthralgia                             | 90 (15.2)      | 92 (25.2)      | <.001b  | 0.550|
| Pantalgia                              | 406 (68.7)     | 122 (33.4)     | <.001b  | 0.676|
| Nausea                                 | 427 (72.3)     | 185 (50.7)     | <.001b  | 0.608|
| Vomiting                               | 213 (36.0)     | 112 (30.7)     | .089b   | 0.527|
| Abdominal pain                         | 158 (26.7)     | 84 (23.0)      | .199b   | 0.519|
| Diarrhea                               | 224 (37.9)     | 59 (16.2)      | <.001b  | 0.609|
| Blush (n = 634)                        | 28 (10.0)      | 158 (44.6)     | <.001b  | 0.673|
| Neck red (n = 634)                     | 19 (6.8)       | 114 (32.2)     | <.001b  | 0.627|
| Chest red (n = 634)                    | 10 (3.6)       | 88 (24.9)      | <.001b  | 0.606|
| Hemoptysis                             | 7 (1.2)        | 3 (0.8)        | .750d   | 0.502|
| Conjunctival congestion                | 42 (7.1)       | 107 (29.3)     | <.001b  | 0.611|
| Eyelids swelling (n = 634)             | 12 (4.3)       | 48 (13.6)      | <.001b  | 0.546|
| Jaundice                               | 3 (0.5)        | 2 (0.6)        | 1.000d  | 0.500|
| Enlarged lymph nodes                   | 241 (40.8)     | 4 (1.1)        | <.001b  | 0.698|
| Hepatosplenomegaly (n = 634)           | 2 (0.3)        | 3 (0.9)        | 1.000d  | 0.501|
| Oliguria (n = 634)                     | 24 (8.6)       | 71 (20.1)      | <.001b  | 0.557|
| Mucosal hemorrhage                     | 86 (14.6)      | 61 (16.7)      | .368b   | 0.511|
| Rash                                   | 7 (1.2)        | 2 (0.6)        | .495b   | 0.569|
| Petechial or bruise                    | 72 (12.2)      | 30 (8.2)       | .054d   | 0.503|
| Outcome                                |                |                | <.001b  | 0.500|
| Cure                                   | 484 (81.9)     | 351 (96.2)     |         |      |
| Deterioriation                         | 96 (16.2)      | 11 (3.0)       |         |      |
| Fatal when discharged from hospital   | 11 (1.9)       | 3 (0.8)        |         |      |
| Laboratory Parameters on Admission    |                |                |         |      |
| White blood cells, ×10^9/L, median (IQR) | 2.3 (1.6-3.4) | 8.7 (5.6-14.9) | <.001c  | 0.930|
| <4                                     | 474 (80.2)     | 37 (10.1)      | <.001b  | 0.871|
| 4-10                                   | 105 (178)      | 220 (60.3)     |         |      |
| ≥10                                    | 12 (2.0)       | 108 (29.6)     |         |      |
| Platelet counts, ×10^9/L, median (IQR) | 58 (40-81)    | 53 (34-86)     | .269b   | 0.468|
| <50                                    | 212 (35.9)     | 112 (30.7)     | .247b   | 0.528|
| 50-100                                 | 312 (52.8)     | 206 (56.4)     |         |      |
| ≥100                                   | 67 (11.3)      | 47 (12.9)      |         |      |
| Positive urine protein (n = 694)       | 261 (58.1)     | 203 (82.9)     | <.001b  | 0.624|
| Prolonged coagulation time (n = 433)   | 140 (43.1)     | 27 (25.0)      | .001b   | 0.590|

Abbreviations: AUC, area under the curve; HFRS, hemorrhagic fever with renal syndrome; IQR, interquartile range; SD, standard deviation; SFTS, severe fever with thrombocytopenia syndrome.

NOTE: The variables with AUC>0.600 were further entered for multivariate analysis.

*a* t-test.

*b* χ² test.

*c* Non-parametric test.

*d* Fisher exact test.
characteristics of HFRS, was also observed in SFTSV-infected patients. Likewise, thrombocytopenia, as one of the hallmarks of SFTS, was also frequently and comparably recorded in HFRS patients. Despite these atypical features, other indicators, including frequency of previous tick/mouse contact, enlarged lymph nodes, and WBC $\leq 3.4 \times 10^9/L$, remained to be significantly different between 2 types of infections. Moreover, after taking into account these atypical cases, a model that made use of enlarged lymph nodes and WBC counts, together with the classic manifestations such as bluish and low back pain, enabled adequate differential diagnosis between HFRS and SFTS in both endemic areas. Still, the effectiveness of the model needs to be evaluated by further clinical studies in other endemic regions.

CONCLUSIONS

This study had limitations that were inherent to retrospective study. Because SFTS viremia is known to wane quickly from 7 days postadmission [13], some of the SFTSV infection might be missed by both loss of viremia and inadequate timing to develop IgM responses. We made no effort to determine the etiological agents of the remaining negative patients, because SFTS and HFRS were among the top list of endemic diseases with high case fatality. In particular, for SFTS disease, more attention and fear were caused because of its high case fatality and person-to-person transmission via human blood [1, 14]. In case of confirmed SFTSV infection at early illness, strict person protection measures should be adopted. Although there is currently no effective therapy for SFTS patients, several experimental therapies such as plasma exchange therapy [15, 16], intravenous Ig plus steroid [17], and convalescent serum therapy [18] might be beneficial if adopted at early stage of the disease. Therefore, the current findings might provide information to guide prevention measures and clinical practice in endemic regions where both diseases exist.

Supplementary Data

Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.

Acknowledgments

Author contributions. All authors read and approved the final manuscript.

Disclaimer. The funding agencies had no role in the design and conduct of the study, collection, management, analysis, interpretation of the data, preparation, review, or approval of the manuscript.

Financial support. This work was funded by the China Mega-Project for Infectious Diseases (Grant 2018ZX10713002 and 2018ZX10101003), the National Natural Science Foundation of China (Grants 81825019, 81703274, 81722041, and 81621005), the New Star Plan of Science and Technology of Beijing (Grant Z17110000117089), and Qingdao People’s Livelihood Science and Technology Program (14-2-3-29sh).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Liu Q, He B, Huang SY, et al. Severe fever with thrombocytopenia syndrome, an emerging tick-borne zoonosis. Lancet Infect Dis 2014; 14:763–72.
2. Yu XI, Liang MF, Zhang SY, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med 2011; 364:1523–32.
3. Zhan J, Wang Q, Cheng J, et al. Current status of severe fever with thrombocytopenia syndrome in China. Virol Sin 2017; 32:51–62.
4. Yamaji K, Aonuma H, Kanuka H. Distribution of tick–borne diseases in Japan: past patterns and implications for the future. J Infect Chemother 2018; 24:499–504.
5. Im HH, Baek J, Durey A, et al. Current status of tick-borne diseases in South Korea. Vector Borne Zoonotic Dis 2019; 19:225–33.
6. Tran XC, Yun Y, Van An L, et al. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis 2019; 25:1029–31.
7. Yu XJ, Tesh RB. The role of mites in the transmission and maintenance of Hantaan virus (Hantavirus: Bunyaviridae). J Infect Dis 2014; 210:1693–9.
8. Jiang H, Zheng X, Wang L, et al. Hantavirus infection: a global zoonotic challenge. Virol Sin 2017; 32:32–43.
9. Zhang S, Wang S, Yin W, et al. Epidemiologic characteristics of hemorrhagic fever with renal syndrome in China, 2006–2012. BMC Infect Dis 2014; 14:384.
10. Qi R, Qin XR, Wang L, et al. Severe fever with thrombocytopenia syndrome can masquerade as hemorrhagic fever with renal syndrome. PLoS Negl Trop Dis 2019; 13:e0007308.
11. Chinese Center for Disease Control and Prevention. Diagnosis and treatment scheme of severe fever and thrombocytopenia syndrome. Available at: http://www.chinacdc.cn/did/crbzt/dwyxhjcmcrb/txbxshjszh/fxbxshyrzl/lgbdkg/lgdkfa/201507/t20150709_116135.html. Accessed 09 July 2015.
12. Chinese Center of Disease Control and Prevention. Monitoring program for epidemic haemorrhagic fever. Available at: http://www.chinacdc.cn/did/crbzt/dwyxhjcmcrb/lxxcxr/lxxcxyyzl/lxxcxjrcl/lxxcxjrclf/201506/t20150618_116135.html. Accessed 18 June 2015.
13. Yang ZD, Hua JG, Lu QB, et al. The prospective evaluation of viral loads in patients with severe fever with thrombocytopenia syndrome. J Clin Virol 2016; 78:123–8.
14. Li H, Lu QB, Xing B, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011–17: a prospective observational study. Lancet Infect Dis 2018; 18:1127–37.
15. Oh WS, Heo ST, Kim SH, et al. Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome. Int J Infect Dis 2014; 18:84–6.
16. Park SY, Choi W, Chong YP, et al. Use of plasma therapy for severe fever with thrombocytopenia syndrome encephalopathy. Emerg Infect Dis 2016; 22:1306–8.
17. Kim UJ, Kim DM, Ahn JH, et al. Successful treatment of rapidly progressing severe fever with thrombocytopenia syndrome with neurological complications using intravenous immunoglobulin and corticosteroid. Antivir Ther 2016; 21:637–40.
18. Shimada S, Posadas-Herrera G, Aoki K, et al. Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection. Virology 2015; 482:19–27.